The Effect of Apomorphine Therapy in the Coexistence of Parkinson’s Disease and Myasthenia Gravis: A Case Report and Review of the Literature
1Department of Neurology, Selahaddin Eyyubi State Hospital, Diyarbakir, Türkiye
2Department of Neurology, Dicle University Faculty of Medicine, Diyarbakir, Türkiye
3Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
J Clin Pract Res 2024; 46(3): 305-308 DOI: 10.14744/cpr.2024.94596
Full Text PDF


Background: The simultaneous occurrence of Parkinson’s disease (PD)—a progressive neurodegenerative disorder marked by the loss of monoaminergic neurons in the substantia nigra—and Myasthenia gravis (MG)—a neuromuscular junction disease—is exceptionally rare. Although these conditions have different pathophysiological foundations, literature reports at least 29 cases of individuals diagnosed with both disorders.
Case Report: We present the case of a 66-year-old patient treated for Parkinson’s disease for four years before being diagnosed with MG, following the onset of dysphagia and bilateral ptosis. Apomorphine infusion, an advanced treatment option, was safely initiated.
Conclusion: This case highlights the coexistence of PD and MG and illustrates the potential benefits of apomorphine infusion therapy. Apomorphine was effective in reducing symptoms, improving motor function, and enhancing the patient’s quality of life.